Atherosclerosis is the leading cause of death globally — responsible for myocardial infarction, stroke, peripheral artery disease, and renal artery stenosis. Yet atherosclerosis is not primarily a cholesterol storage disease — it is a chronic inflammatory disease of the arterial wall in which oxidized lipoproteins, immune activation, endothelial dysfunction, and metabolic dysregulation drive progressive plaque formation over decades. A root cause integrative approach addresses the upstream drivers of arterial inflammation and endothelial injury rather than focusing exclusively on cholesterol lowering.
Pathophysiology: How Plaques Form
Atherosclerosis begins with endothelial dysfunction — loss of the protective nitric oxide (NO)-generating capacity of the arterial endothelium. Damaged endothelium becomes adhesive, permeable, and pro-inflammatory, allowing oxidized LDL (oxLDL) to enter the subintimal space. Monocytes are recruited and differentiate into macrophages that engulf oxLDL, becoming foam cells — the hallmark of the early atherosclerotic lesion (fatty streak). As inflammation progresses, smooth muscle cells migrate from the media, a fibrous cap forms over the lipid-rich necrotic core, and the plaque grows. Vulnerable plaques — those with thin fibrous caps, large lipid cores, and active inflammation — are prone to rupture, triggering thrombosis and acute coronary events. Plaque stability, not plaque size, determines cardiovascular event risk.
Root Causes and Pathogenic Drivers
Endothelial Dysfunction and Nitric Oxide Deficiency
The endothelium produces nitric oxide (NO) via eNOS — NO maintains vasodilation, inhibits platelet aggregation, prevents monocyte adhesion, and suppresses smooth muscle cell proliferation. Endothelial dysfunction (reduced NO bioavailability) is the initiating event in atherosclerosis, preceding visible plaque by years to decades. Drivers of endothelial dysfunction include oxidative stress (superoxide quenches NO), insulin resistance (impairs insulin-stimulated eNOS activation), hypertension, advanced glycation end-products (AGEs), homocysteine excess, and chronic inflammation.
Oxidized LDL and Lipid Peroxidation
Native LDL does not cause atherosclerosis — oxidized LDL (oxLDL) does. LDL becomes atherogenic when oxidized by reactive oxygen species, myeloperoxidase, or lipoxygenase in the arterial wall. Small dense LDL particles (pattern B) are the most atherogenic — more easily oxidized, longer arterial residence time, and greater subintimal penetration than large buoyant LDL. Measuring LDL particle number (LDL-P via NMR) and oxLDL is more predictive of cardiovascular risk than total LDL-C alone. The ratio of triglycerides to HDL (TG:HDL ratio greater than 2.0) is a reliable marker of small dense LDL predominance and insulin resistance-driven atherogenic dyslipidemia.
Chronic Inflammation
High-sensitivity CRP, IL-6, TNF-alpha, and lipoprotein-associated phospholipase A2 (Lp-PLA2) are independent cardiovascular risk predictors beyond LDL. The JUPITER trial demonstrated that rosuvastatin reduced major cardiovascular events by 44% in patients with normal LDL but elevated CRP — confirming inflammation as an independent atherogenic driver. NLRP3 inflammasome activation in macrophages within plaques drives IL-1 beta release, promoting plaque vulnerability and rupture. The CANTOS trial demonstrated that canakinumab (IL-1 beta antibody) reduced recurrent MI independently of any lipid effects — proof-of-concept that inflammation is a direct therapeutic target in atherosclerosis.
Insulin Resistance and Metabolic Syndrome
Insulin resistance drives atherosclerosis through multiple parallel mechanisms: hyperinsulinemia promotes hepatic VLDL overproduction (raising triglycerides and small dense LDL), impairs HDL function and reverse cholesterol transport, promotes endothelial dysfunction by reducing insulin-stimulated NO production, increases oxidative stress, and drives the chronic inflammatory state that is the proximate cause of plaque progression. Metabolic syndrome (insulin resistance plus hypertension plus dyslipidemia plus central obesity) multiplies cardiovascular risk. Cross-reference: Insulin Resistance and Metabolic Syndrome.
Homocysteine Excess
Homocysteine is a sulfur-containing amino acid that is directly toxic to the endothelium — it promotes oxidative stress, impairs NO bioavailability, activates NF-kB-driven inflammation, promotes smooth muscle cell proliferation, and increases LDL oxidation. Hyperhomocysteinemia (greater than 10 micromol/L) significantly increases cardiovascular risk. Driven by deficiencies in B6, B12, folate (MTHFR polymorphisms impair homocysteine methylation), and renal insufficiency. Homocysteine measurement and B-vitamin-based lowering is an underutilized cardiovascular intervention.
Gut Dysbiosis and TMAO
Trimethylamine N-oxide (TMAO) is produced by gut bacteria from dietary choline and carnitine (red meat, eggs) — elevated TMAO is independently associated with atherosclerosis progression and major adverse cardiovascular events. TMAO promotes foam cell formation, inhibits reverse cholesterol transport, and activates platelet aggregation. Gut dysbiosis increases TMAO-producing bacterial species (Firmicutes). TMAO measurement is an emerging cardiovascular biomarker. Cross-reference: Leaky Gut: Root Causes and Integrative Recovery.
Oxidative Stress and Myeloperoxidase
Myeloperoxidase (MPO) released by activated macrophages within plaques oxidizes LDL, consumes NO (worsening endothelial dysfunction), and generates hypochlorous acid that destabilizes the fibrous cap. Elevated serum MPO predicts cardiovascular events independently of traditional risk factors. Systemic oxidative stress (measured by F2-isoprostanes, oxidized glutathione, or 8-OHdG) reflects the atherogenic environment and is reduced by antioxidant nutrients and lifestyle interventions.
Hypercoagulability and Platelet Activation
Fibrinogen excess, elevated Lp(a), platelet hyperreactivity, and impaired fibrinolysis shift the hemostatic balance toward thrombosis — determining whether plaque rupture causes a fatal event. Lp(a) is genetically determined, pro-inflammatory, and pro-thrombotic — elevated Lp(a) (greater than 50 mg/dL) is an independent cardiovascular risk factor for which targeted therapies are emerging.
Chronic Infections
Chlamydia pneumoniae, P. gingivalis (periodontal disease), Helicobacter pylori, and CMV have been detected within atherosclerotic plaques and are associated with accelerated plaque progression. Periodontal disease is one of the most consistently established independent risk factors for cardiovascular events — oral bacteria translocate to coronary arteries and drive local inflammatory responses. Dental hygiene is a legitimate cardiovascular intervention.
Diagnostic Assessment
- Advanced lipid panel: LDL particle number (LDL-P), small dense LDL, HDL function, Lp(a), apolipoprotein B (ApoB is the most direct measure of atherogenic particle burden)
- Inflammatory markers: High-sensitivity CRP (target below 1.0 mg/L), Lp-PLA2, MPO, IL-6
- Metabolic assessment: Fasting insulin, HOMA-IR, HbA1c, TG:HDL ratio (target below 2.0)
- Homocysteine: Target below 8 micromol/L; assess MTHFR status
- Oxidative stress: oxLDL, F2-isoprostanes, MPO
- TMAO: Fasting plasma TMAO — emerging cardiovascular risk marker
- Coronary artery calcium (CAC) score: Most powerful predictor of cardiovascular events — CAC of 0 confers very low 10-year risk; CAC above 300 indicates high risk requiring aggressive intervention
- Carotid intima-media thickness (CIMT): Structural atherosclerosis measurement — useful for monitoring regression
- 25(OH)D: Vitamin D deficiency accelerates endothelial dysfunction and plaque progression
Conventional Treatment
Statins
Most evidence-based lipid-lowering therapy — reduce LDL-C by 30-50%, reduce cardiovascular events by 25-35% in high-risk populations. Mechanism extends beyond LDL lowering to pleiotropic anti-inflammatory and endothelial-protective effects (reduced NF-kB, increased eNOS expression). High-intensity statin therapy (rosuvastatin 20-40mg, atorvastatin 40-80mg) is indicated for established ASCVD. Statins deplete CoQ10 — supplementation 200-400mg ubiquinol daily is recommended for all statin users.
PCSK9 Inhibitors
Alirocumab and evolocumab reduce LDL-C by 50-60% on top of statin therapy by blocking PCSK9-mediated LDL receptor degradation. Demonstrated significant cardiovascular event reduction in statin-intolerant and very high-risk patients. Inclisiran (siRNA-based PCSK9 inhibition) requires only twice-yearly injection.
Ezetimibe
Reduces intestinal cholesterol absorption by 15-20% (additive to statins). IMPROVE-IT trial demonstrated significant cardiovascular event reduction when added to statin in post-ACS patients.
Aspirin
Low-dose aspirin (81mg) is established for secondary prevention (prior MI or stroke) but current guidelines no longer recommend primary prevention aspirin in most patients due to bleeding risk offsetting cardiovascular benefit.
Repurposed Drugs with Atherosclerosis Evidence
Colchicine
The LoDoCo2 trial (2020) demonstrated colchicine 0.5mg daily reduced major cardiovascular events by 31% in stable coronary artery disease patients — purely via NLRP3 inflammasome inhibition and reduction of vascular inflammation independent of any lipid effects. This established anti-inflammatory therapy as a proven cardiovascular intervention beyond lipid lowering. Well tolerated at low doses long-term.
Metformin
Beyond diabetes management — metformin activates AMPK, which reduces hepatic lipogenesis, improves endothelial NO production, reduces oxidative stress, inhibits vascular smooth muscle cell proliferation, and reduces systemic inflammation. The UKPDS trial demonstrated cardiovascular benefits of metformin beyond glycemic control. Strongly considered in insulin-resistant atherosclerosis patients. Cross-reference: Berberine: The Metabolic Modulator for botanical AMPK activation.
Low-Dose Naltrexone
LDN reduces systemic inflammation via microglial modulation and TLR4 antagonism — reducing the cytokine-driven inflammatory environment that drives plaque progression and vulnerability. Also improves insulin sensitivity and reduces oxidative stress load. Dose: 1.5-4.5mg nightly. Cross-reference: LDN Guide.
RAAS Inhibitors
ACE inhibitors and ARBs reduce angiotensin II-driven endothelial inflammation, oxidative stress, and smooth muscle cell proliferation in the arterial wall — effects that are partially independent of blood pressure reduction. HOPE trial demonstrated ramipril reduced MI, stroke, and cardiovascular death by 22% in high-risk patients without heart failure or reduced EF.
Vitamins, Supplements and Compounds
Omega-3 Fatty Acids (EPA and DHA)
EPA and DHA reduce triglycerides (by 20-50% at 4g/day), reduce systemic inflammation (reducing CRP, IL-6, TNF-alpha), improve endothelial function (increasing NO bioavailability), reduce platelet aggregation, and stabilize vulnerable plaques. The REDUCE-IT trial demonstrated that high-dose icosapentaenoic acid (EPA 4g/day as icosapentaenoic acid ethyl ester) reduced major cardiovascular events by 25% in statin-treated patients with elevated triglycerides — independent of triglyceride lowering alone. Omega-3 index target greater than 8%. Dose: 2-4g EPA plus DHA daily.
Berberine
Berberine activates AMPK (same pathway as metformin) — reducing hepatic LDL production, increasing LDL receptor expression, improving insulin sensitivity, reducing inflammation, and inhibiting smooth muscle cell proliferation in the arterial wall. Multiple RCTs demonstrate berberine reduces LDL-C by 20-25%, triglycerides by 35%, and CRP in dyslipidemic patients. Dose: 500mg twice to three times daily. Cross-reference: Berberine: The Metabolic Modulator.
CoQ10 (Ubiquinol)
CoQ10 is an essential mitochondrial antioxidant and electron carrier — reducing oxidative stress in the arterial wall and protecting LDL from oxidation. Statin-depleted CoQ10 impairs endothelial function and increases cardiovascular risk. Supplementation improves endothelial function, reduces oxLDL, and reduces blood pressure. Dose: 200-400mg ubiquinol daily. Essential for all statin users.
Vitamin K2 (MK-7)
Vitamin K2 activates matrix Gla protein (MGP) — the most potent known inhibitor of arterial calcification. Inactive (uncarboxylated) MGP allows calcium to deposit in arterial walls, progressively stiffening arteries and converting soft plaques to calcified (more stable but less reversible) lesions. K2 deficiency is extremely common and directly contributes to arterial calcification. The Rotterdam study demonstrated K2 intake inversely correlated with cardiovascular mortality and aortic calcification. Dose: K2 MK-7 100-200mcg daily (always combined with D3).
Vitamin D3
Vitamin D deficiency activates RAAS (increasing angiotensin II and arterial inflammation), promotes endothelial dysfunction, and increases cardiovascular risk. Supplementation reduces blood pressure, improves endothelial function, and reduces inflammatory markers. Dose: 3,000-5,000 IU D3 daily plus K2 (target 60-80 ng/mL).
Magnesium
Magnesium reduces arterial stiffness, lowers blood pressure, reduces platelet aggregation, and impairs the calcification of arterial smooth muscle cells. Deficiency accelerates all of these processes. Dose: 300-400mg elemental magnesium glycinate or malate daily.
Niacin (Vitamin B3)
Extended-release niacin raises HDL by 20-30% (the most effective HDL-raising intervention available), reduces Lp(a) by 20-30%, reduces triglycerides, and shifts LDL from small dense to large buoyant pattern. The AIM-HIGH and HPS2-THRIVE trials showed neutral cardiovascular outcomes when added to intensive statin therapy — suggesting the benefit may be greatest in pre-statin or statin-intolerant patients, or those with elevated Lp(a). Dose: 1,000-2,000mg extended-release niacin daily (titrate slowly to reduce flushing; take aspirin 30 minutes prior).
Methylated B Vitamins (B6, B12, Folate)
Homocysteine lowering via methylated B vitamins (methylcobalamin, methylfolate, P5P) reduces endothelial toxicity and LDL oxidation. MTHFR C677T homozygotes require methylated forms — folic acid supplementation does not adequately reduce homocysteine in these patients. Target homocysteine below 8 micromol/L. Dose: methylfolate 400-800mcg, methylcobalamin 1,000mcg, B6 (P5P) 25-50mg daily.
Tocotrienols (Vitamin E Complex)
Tocotrienols (particularly delta and gamma) are superior to tocopherols for cardiovascular protection — inhibiting HMG-CoA reductase (modest LDL reduction), reducing LDL oxidation, inhibiting platelet aggregation, and reducing arterial inflammation. Multiple studies demonstrate tocotrienols reduce carotid CIMT and regress existing plaque. Dose: 100-200mg tocotrienol complex daily.
Botanical Treatments
Berberine (Botanical Source)
As above — from Berberis aristata or Hydrastis canadensis. The botanical equivalent of a combined statin plus metformin for dyslipidemia and insulin resistance, with direct anti-atherogenic effects on arterial smooth muscle and endothelium.
Curcumin
Curcumin reduces NF-kB-driven arterial inflammation, reduces oxLDL, inhibits platelet aggregation, improves endothelial function (increasing NO bioavailability), and reduces CRP. Multiple clinical studies demonstrate curcumin reduces CIMT and improves endothelial function in atherosclerosis patients. Use phospholipid complex or nanoparticle form for bioavailability. Dose: 500-1,000mg curcumin phytosome daily. Cross-reference: Curcumin: The Anti-Inflammatory Compound.
Aged Garlic Extract
Aged garlic extract (AGE) reduces LDL oxidation, inhibits platelet aggregation, reduces blood pressure, reduces CRP, and has demonstrated plaque regression in RCTs. The EVADER trial demonstrated AGE plus CoQ10 significantly reduced coronary plaque volume on CT angiography. Dose: 1,200-2,400mg AGE daily.
Hawthorn
Hawthorn flavonoids and proanthocyanidins reduce arterial oxidative stress, improve coronary vasodilation, reduce LDL oxidation, and have mild ACE-inhibitory effects reducing arterial stiffness. Well-established cardiovascular botanical with excellent safety profile. Dose: 600-900mg standardized extract daily.
Resveratrol
Resveratrol activates SIRT1 (deacetylase that improves endothelial function and reduces NF-kB inflammation), inhibits LDL oxidation, reduces platelet aggregation, and improves insulin sensitivity. Bioavailability is limited with standard preparations — use liposomal or micronized resveratrol. Dose: 250-500mg daily. Cross-reference: Resveratrol.
EGCG (Green Tea Extract)
EGCG reduces LDL oxidation, inhibits macrophage foam cell formation, improves endothelial NO production, reduces platelet aggregation, and reduces inflammatory markers. Multiple epidemiological studies associate green tea consumption with reduced cardiovascular mortality. Dose: 400-800mg EGCG extract daily. Cross-reference: EGCG: Green Tea Extract.
Diet and Lifestyle
Mediterranean diet has the strongest evidence for cardiovascular risk reduction — the PREDIMED trial demonstrated a 30% reduction in major cardiovascular events with Mediterranean diet supplemented with olive oil or nuts vs. low-fat diet. Anti-inflammatory, high in omega-3, polyphenols, fiber, and potassium; low in refined carbohydrates and trans fats.
Eliminate seed oils and trans fats: Industrial seed oils (corn, soybean, sunflower) are rich in omega-6 linoleic acid that is highly susceptible to oxidation and incorporation into LDL, increasing atherogenicity. Replace with olive oil, avocado oil, and coconut oil.
Reduce refined carbohydrates and sugar: Fructose-driven hepatic lipogenesis is the primary driver of elevated triglycerides and small dense LDL pattern — the most atherogenic lipid phenotype. Carbohydrate restriction reduces TG:HDL ratio more effectively than fat restriction.
Exercise: 150 minutes per week of moderate aerobic exercise improves endothelial function (upregulating eNOS), reduces inflammation, improves insulin sensitivity, raises HDL, and reduces triglycerides. Resistance training additionally reduces visceral adiposity and insulin resistance.
Stress reduction: Chronic psychological stress activates sympathetic tone, raises cortisol, worsens insulin resistance, and promotes platelet activation — all atherogenic. Mindfulness-based stress reduction reduces CRP and cardiovascular event risk.
Sleep: Short sleep duration (less than 6 hours) and poor sleep quality independently increase cardiovascular risk — raising inflammatory markers, blood pressure, and insulin resistance. Target 7-9 hours of quality sleep.
Dental hygiene: Periodontal disease treatment reduces CRP and improves endothelial function — a legitimate cardiovascular intervention. Daily flossing and twice-yearly professional cleaning.
Integrated Protocol
Foundation — All Patients
- Omega-3 index testing; 2-4g EPA plus DHA daily (target omega-3 index above 8%)
- Ubiquinol 200-400mg daily (essential for statin users; beneficial for all)
- Vitamin K2 MK-7 100-200mcg daily plus D3 3,000-5,000 IU
- Magnesium glycinate 300-400mg daily
- Methylated B complex daily (homocysteine reduction)
- Mediterranean anti-inflammatory diet
- Eliminate refined carbohydrates, seed oils, and added sugars
- Exercise: 150 minutes moderate aerobic plus resistance training weekly
- Sleep optimization: 7-9 hours
- Dental hygiene: daily flossing plus professional cleaning twice yearly
Inflammation-Driven Atherosclerosis (High hsCRP)
- Curcumin phytosome 500-1,000mg daily
- Aged garlic extract 1,200-2,400mg daily
- EGCG 400-800mg daily
- Discuss colchicine 0.5mg daily with cardiologist
- Address gut dysbiosis: reduce TMAO-producing bacteria, optimize microbiome
Insulin Resistance and Atherogenic Dyslipidemia
- Berberine 500mg twice to three times daily
- Full insulin resistance protocol (inositol, R-ALA, chromium)
- Target TG:HDL ratio below 2.0
- Consider extended-release niacin for elevated Lp(a) or low HDL
- Discuss metformin with prescriber if insulin resistant
Arterial Calcification Prevention
- K2 MK-7 200mcg daily — non-negotiable
- Magnesium 400-600mg daily (competes with calcium in arterial smooth muscle)
- Tocotrienol complex 100-200mg daily
- Reduce dietary calcium supplementation — dietary calcium preferred over supplements
Elevated Lp(a)
- Extended-release niacin 1,000-2,000mg daily
- Omega-3 high-dose EPA 4g daily
- Liposomal vitamin C 2,000-4,000mg daily (Lp(a) is evolutionarily a surrogate for vitamin C)
- Discuss emerging PCSK9 inhibitors or RNA-targeting therapies with lipidologist
Monitoring
- ApoB, LDL-P, hsCRP, omega-3 index: every 6 months
- Homocysteine, 25(OH)D, RBC magnesium: every 6 months
- HbA1c, fasting insulin, TG:HDL ratio: every 6 months
- CAC score: baseline then every 3-5 years (tracks calcification progression or arrest)
- CIMT: annually in high-risk patients (tracks intima-media thickness regression)
Key Citations
- Ridker PM et al. Antiinflammatory therapy with canakinumab for atherosclerotic disease (CANTOS). NEJM. 2017.
- Nidorf SM et al. Colchicine in patients with chronic coronary disease (LoDoCo2). NEJM. 2020.
- Bhatt DL et al. Cardiovascular risk reduction with icosapentaenoic acid (REDUCE-IT). NEJM. 2019.
- Estruch R et al. Primary prevention of cardiovascular disease with Mediterranean diet (PREDIMED). NEJM. 2013.
- Ridker PM et al. Rosuvastatin to prevent vascular events in men and women with elevated CRP (JUPITER). NEJM. 2008.
0 comments